BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38176176)

  • 1. Integration of substance use disorder treatment in traditional mental health facilities: Timeseries and cross-sectional evaluations.
    Garrison YL; Luo Y; Sahker E
    Int J Drug Policy; 2024 Feb; 124():104312. PubMed ID: 38176176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of Trauma-Specific Services in US Substance Use Disorder and Other Mental Health Treatment Facilities: 2015-2019.
    Spivak S; Spivak A; Decker MR; Cullen B; Yao M; Mojtabai R
    Psychiatr Q; 2022 Sep; 93(3):703-715. PubMed ID: 35612755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classifying substance use disorder treatment facilities with co-located mental health services: A latent class analysis approach.
    Mauro PM; Furr-Holden CD; Strain EC; Crum RM; Mojtabai R
    Drug Alcohol Depend; 2016 Jun; 163():108-15. PubMed ID: 27106113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mental health facilities with ketamine infusion therapy in the United States in 2020: Co-location of dual diagnosis mental health and substance use disorder treatment.
    Ware OD
    Exp Clin Psychopharmacol; 2024 Jun; 32(3):263-269. PubMed ID: 37917509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in cigarette use and health insurance coverage among US adults with mental health and substance use disorders.
    Creedon TB; Wayne GF; Progovac AM; Levy DE; Cook BL
    Addiction; 2023 Feb; 118(2):353-364. PubMed ID: 36385708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health facility readiness to screen, diagnose and manage substance use disorders in Mbale district, Uganda.
    Aber-Odonga H; Nuwaha F; Kisaakye E; Engebretsen IMS; Babirye JN
    Subst Abuse Treat Prev Policy; 2023 Nov; 18(1):63. PubMed ID: 37925411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electronic health record adoption among US substance use disorder and other mental health treatment facilities.
    Spivak S; Strain EC; Cullen B; Ruble AAE; Antoine DG; Mojtabai R
    Drug Alcohol Depend; 2021 Mar; 220():108515. PubMed ID: 33461154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment use, perceived need, and barriers to seeking treatment for substance abuse and mental health problems among older adults compared to younger adults.
    Choi NG; DiNitto DM; Marti CN
    Drug Alcohol Depend; 2014 Dec; 145():113-20. PubMed ID: 25456572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mental health facilities with eating disorder treatment programs and substance use disorder treatment in the United States.
    Ware OD; Neukrug H; Goode RW
    Eat Disord; 2024; 32(4):387-400. PubMed ID: 38314747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of mental health and substance use disorder treatment use over 3 years among rural adults using stimulants.
    Cucciare MA; Ounpraseuth ST; Curran GM; Booth BM
    Subst Abus; 2019; 40(3):363-370. PubMed ID: 30810499
    [No Abstract]   [Full Text] [Related]  

  • 11. Patterns in Geographic Distribution of Substance Use Disorder Treatment Facilities in the US and Accepted Forms of Payment From 2010 to 2021.
    Cantor JH; DeYoreo M; Hanson R; Kofner A; Kravitz D; Salas A; Stein BD; Kapinos KA
    JAMA Netw Open; 2022 Nov; 5(11):e2241128. PubMed ID: 36367729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mental Health Parity and Addiction Equity Act (MHPAEA) evaluation study: Did parity differentially affect substance use disorder and mental health benefits offered by behavioral healthcare carve-out and carve-in plans?
    Friedman SA; Azocar F; Xu H; Ettner SL
    Drug Alcohol Depend; 2018 Sep; 190():151-158. PubMed ID: 30032052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining facilitative services for entry into substance use disorder treatment: A cluster analysis of treatment facilities.
    Amoako EO; Zerden LD; Hughes TD; Gertner AK; Williams J; Belden CM; Ware OD
    PLoS One; 2024; 19(5):e0304094. PubMed ID: 38781169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual use and perceived need for mental health and substance treatment among people in remission from substance use disorders in the United States.
    Hayes BB
    Drug Alcohol Depend; 2023 Aug; 249():110820. PubMed ID: 37329728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.
    Wen H; Cummings JR; Hockenberry JM; Gaydos LM; Druss BG
    JAMA Psychiatry; 2013 Dec; 70(12):1355-62. PubMed ID: 24154931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Special Services for Women in Substance Use Disorders Treatment: How Does the Department of Veterans Affairs Compare with Other Providers?
    Heslin KC; Gable A; Dobalian A
    Womens Health Issues; 2015; 25(6):666-72. PubMed ID: 26329259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance Use Disorder Treatment Services for Women in the Veterans Health Administration.
    Timko C; Hoggatt KJ; Wu FM; Tjemsland A; Cucciare M; Rubin A; Simpson TL
    Womens Health Issues; 2017; 27(6):639-645. PubMed ID: 28602581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of substance use disorder treatment initiation and engagement among adolescents enrolled in Medicaid.
    Chavez LJ; Steelesmith DL; Bridge JA; Fontanella CA
    Subst Abus; 2022; 43(1):1260-1267. PubMed ID: 35670769
    [No Abstract]   [Full Text] [Related]  

  • 19. Facility and state-level factors associated with telemental health (TMH) adoption among mental health facilities in the United States.
    Zhao X; Innes KE; Bhattacharjee S; Dwibedi N; LeMasters TM; Sambamoorthi U
    J Telemed Telecare; 2021 May; 27(4):244-257. PubMed ID: 31475879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions of mental health and substance use disorder services integration among the workforce in primary care settings.
    Urada D; Schaper E; Alvarez L; Reilly C; Dawar M; Field R; Antonini V; Oeser B; Crèvecoeur-MacPhail D; Rawson RA
    J Psychoactive Drugs; 2012; 44(4):292-8. PubMed ID: 23210377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.